AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04331067 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow
Description: -Time of port placement (baseline), time of surgery, and time of recurrence (optional)
Study NCT04331067 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood draw
Description: -Baseline, week 5, prior to surgery , post-surgery follow-up (typically 3-4 weeks post-surgery), and disease progression (optional)
Study NCT04331067 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood draw
Description: -Baseline, week 5, prior to surgery , post-surgery follow-up (typically 3-4 weeks post-surgery), and disease progression (optional)
Study NCT02542241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Chloride [3%]
Description: Patients in this arm will receive an intravenous infusion of 3% hypertonic saline at a 50 cc/hour rate, which will be administered by an infusion pump during the first 72 hours after the damage control surgery. A total of 3600cc will be administered throughout 72 hours ( 1200cc every 24 hours).
Study NCT01044342 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsule, single oral dose
Study NCT02817620 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Spirulysat®
Study NCT02817620 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02493218 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Instruction
Description: Age-appropriate instruction on mindfulness concepts and practices, adapted from the mindfulness-based stress reduction (MBSR) program. Classes are 45-90 minutes each and held weekly for 12 weeks.
Study NCT02493218 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: Age-appropriate health education concepts and topics. Classes are 45-90 minutes each and held weekly for 12 weeks.
Study NCT02542241 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Chloride [0.9%]
Description: Patients in this arm will receive an intravenous infusion of 0.9% hypertonic saline at a 50 cc/hour rate, which will be administered by an infusion pump during the first 72 hours after the damage control surgery. A total of 3600cc will be administered throughout 72 hours ( 1200cc every 24 hours).
Study NCT01004224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGJ398
Study NCT03180658 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GTR + CGF + bone graft
Description: Guided tissue regeneration (GTR) combined with CGF and bone graft to treat mandibular furcation involvements
Study NCT03180658 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CGF + bone graft
Description: CGF combined with bone graft to treat mandibular furcation involvements
Study NCT02351193 — intervention group
Intervention type: OTHER
Intervention: transvaginal Ultrasound
Study NCT06369519 — intervention group
Intervention type: PROCEDURE
Intervention: Surgery treatment or local tumor destruction.
Description: Surgery treatments mainly include partial nephrectomy and radical nephrectomy. Local tumor destruction mainly includes renal mass ablation.
Study NCT03048123 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hepatic arterial infusion
Description: A standard hepatic artery catheter was introduced via the femoral artery percutaneously. Selective catheterization of the proper hepatic artery was performed using standard diagnostic catheters and fluoroscopic guidance. In the event of multiple arterial supply(including superior-mesenteric artery), the proportion of the liver supplied by each artery was estimated by the arteriogram. After optimal positioning of the catheter in dominant supplying artery to ensure minimal reflux, the catheter was fixed and connected with infusion tube. In the condition of multiple tumors on both left and right lobe, the gastroduodenal artery was embolized and the catheter was positioned in the hepatic proper artery for infusion. Folfox Protocol were infused through the fixed catheter sequentially
Study NCT03048123 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transarterial chemoembolization
Description: Previous procedure was same with hepatic arterial infusion chemotherapy. After optimal positioning of the catheter, TACE Drug Protocol were injected.
Study NCT03048123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folfox Protocol
Description: oxaliplatin,leucovorin and 5-FU
Study NCT03048123 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TACE Drug Protocol
Description: lipiodol mixed with chemotherapy drugs(EADM , lobaplatin, and MMC) followed by polyvinyl alcohol particles (PVA)
Study NCT04958148 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Salt pills
Description: Subjects will supplement salt pills with meals.
Study NCT04958148 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pills
Description: Subjects will supplement placebo pills with meals.
Study NCT02434172 — intervention group
Intervention type: OTHER
Intervention: Pre-emptive screening and treatment for cryptococcal disease
Description: Preemptive screening for cryptococcal disease among individuals with CD4 counts below 100 cells/mm3 with anti fungal therapy for those what are Cryptococcus antigen positive. These participants will be followed longitudinally for 12 months to determine clinical outcome, with their outcome compared with similar patients who are cryptococcal antigen negative, who will also be followed longitudinally for 12 months.
Study NCT04000737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YIV-906+Sorafenib
Description: Patients will be given sorafenib (400 mg BID) daily for a 28-day course with YIV-906 (3 capsules, BID) 4 days on and 3 days off weekly in each course.
Study NCT04000737 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo+Sorafenib
Description: Patients will be given sorafenib (400 mg BID) daily for a 28-day course with placebo (3 capsules, BID) 4 days on and 3 days off weekly in each course.
Study NCT02049840 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Altis Single Incision Sling System
Description: Altis Single Incision Sling (SIS) System is a permanently implantable synthetic sling for the surgical treatment of Stress Urinary Incontinence
Study NCT02994459 — intervention group
Intervention type: OTHER
Intervention: Weight Loss
Description: Diet-induced weight loss (obese only)
Study NCT02174913 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: bispectral index
Description: Bispectral index (BIS) is one of several technologies used to monitor depth of anesthesia.
Study NCT02174913 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Target controlled infusion of propofol
Description: TCI propofol (3-7 mcg/dL, Schnider model) is used for total intravenous anesthesia in both groups
Study NCT02174913 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Target controlled infusion of propofol
Description: TCI propofol (3-7 mcg/dL, Schnider model) is used for total intravenous anesthesia in both groups
Study NCT02174913 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl 1-2 mcg/kg iv for induction and then 0.5-1.0 mcg/kg/hr infusion is used for analgesic.
Study NCT02174913 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl 1-2 mcg/kg iv for induction and then 0.5-1.0 mcg/kg/hr infusion is used for analgesic.
Study NCT02174913 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atracurium
Description: Atracurium 0.6 mg/kg is used for endotracheal intubation
Study NCT02174913 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atracurium
Description: Atracurium 0.6 mg/kg is used for endotracheal intubation
Study NCT04658524 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Thyroid function
Description: laboratorial thyroid tests
Study NCT01173055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: milnacipran
Description: Milnacipran will be given orally twice daily in tablet form at different times during the course of the study. The highest dose of milnacipran to be used in the study is 200mg/day.
Study NCT01173055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be given orally twice daily in tablet form at different times during the course of the study.
Study NCT02083185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relugolix
Description: Relugolix tablets
Study NCT02083185 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprorelin
Description: Leuprorelin subcutaneous injection
Study NCT02406300 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subarachnoid Anesthesia
Study NCT02406300 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PNB/GA
Study NCT02406300 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine
Study NCT02406300 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevoflurane or desflurane
Study NCT02406300 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine or levobupivacaine
Study NCT03754634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag and Diacerein
Description: The initial dose of eltrombopag administration is 25 mg orally once daily, which could be transited to 50 mg/d in a 2-week cycle according to the need, and the maximum dose was not more than 75 mg/d. The dose of diacerein administration is 50 mg orally twice daily. The treatment was discontinued after 6 weeks without blood index reaction.
Study NCT01117233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04427429
Description: single intravenous infusion of 10 mg PF-04427429 or placebo
Study NCT01117233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04427429
Description: single intravenous infusion of 30 mg PF-04427429 or placebo
Study NCT01117233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04427429
Description: single intravenous infusion of 100 mg PF-04427429 or placebo
Study NCT01117233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04427429
Description: single intravenous infusion of 300 mg PF-04427429 or placebo
Study NCT01117233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04427429
Description: single intravenous infusion of 1000 mg PF-04427429 or placebo
Study NCT02319720 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspirate
Description: Fresh bone marrow aspirate administered to the wound at the time the bone marrow is taken.
Study NCT02319720 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cultured Bone Marrow Cells
Description: The bone marrow aspirate will be sent to the laboratory to be grown in tissue culture. Once the cell cultures have matured (within 8 weeks) they will be checked for sterility and frozen until applied to the subject's wound.
Study NCT02319720 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Control
Description: The subjects in this group will receive currently approved treatments for their wound. These treatments will include debridement and dressing changes. Wound dressings allowed will include gauze, foam dressings, occlusive films, and non-stick pads. More advanced dressing materials such as Hydrocolloids, alginates, silver containing dressings, and biomaterials can also be used. Compression will be utilized for lower extremity wounds.
Study NCT02319720 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The subjects in this group will receive currently approved treatments for their wound. These treatments will include debridement and dressing changes. Wound dressings allowed will include gauze, foam dressings, occlusive films, and non-stick pads. More advanced dressing materials such as Hydrocolloids, alginates, silver containing dressings, and biomaterials can also be used. Compression will be utilized for lower extremity wounds.
Study NCT01157650 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous mesenchymal stem cells
Description: The trial is divided in three phases:~I. - Selection: Patients evaluation for study eligibility will take place within two weeks after Informed Consent signature.~II.- Treatment phase includes:~1. Liposuction procedure to obtain adipose tissue.~2. Processing and production of Autologous Mesenchymal Stem Cells from adipose tissue (ASCs)~3. ASCs implant~III.- Follow up: Study visits post-implant will take place at the 1st week (+/- 3 days), 4th week (+/- 3 days), 8th week (+/- 7 days), 12nd week (+/- 7 days), 24th week (+/- 7 days), and 1 year (+/- 7 days) after implant.
Study NCT04303533 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuro-Feedback EFP
Description: Neurofeedback (NF) - is a treatment method based on learned self-modulation of neural activity in response to feedback of neural signal. Amygdala-EFP (EEG-finger-print, EFP) is an EEG-NF application that modulates amygdala response.
Study NCT01588457 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lithium
Description: Therapeutic dosage as indicated by participants condition with blood levels. LI will be dosed to attain Li of ≥0.5mEq/L (milliequivalents per liter).
Study NCT01588457 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Divalproex
Description: DV will be dosed to attain DV levels of ≥45mg/L.
Study NCT01588457 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamotrigine
Description: LM will be incrementally dosed up to 400 mg/day, or, in combination with DV, 200 mg/day. Dosage may be reduced for adverse effects to one half of the target dose.
Study NCT01588457 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine
Description: QT will be started at 50 mg/day and titrated up to 300 mg as tolerated. QT will be discontinued if not tolerated at 100mg/day and the patient will be treated according to guidelines.
Study NCT04738422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alkaline glycine
Description: Subjects will inhale alkaline glycine via nebulizer. Alkaline glycine is an alkaline medication designed for medication.
Study NCT04601103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: No SLS toothpaste
Description: Toothpaste no Sodium Lauryl Sulfate
Study NCT04601103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medium SLS toothpaste
Description: Less than or equal to X ppm Sodium Lauryl Sulfate
Study NCT04601103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High SLS toothpaste
Description: More than or equal to X ppm Sodium Lauryl Sulfate
Study NCT04601103 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anti-plaque
Description: Rinse prevents bacterial adherence to teeth
Study NCT03164473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: pre-emptive 500-mg fixed-dose of IV rituximab every 6 months (total duration of 18 months = 4 infusions)
Study NCT03164473 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine
Description: oral tablets : 2 mg/kg/day for 24 months
Study NCT03164473 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo-rituximab
Description: 4 infusions for 18 months
Study NCT03164473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-azathioprine
Description: oral tablets for 24 months
Study NCT05454540 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION
Description: daily treatment session of REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION will be applied over precuneus for 20 minutes of consecutive blocks of 20Hz pulses for two seconds followed by 28 seconds of no stimulation.~Other Name: RTMS
Study NCT05454540 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION
Description: daily treatment session of REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION will be applied over precuneus for 20 minutes of consecutive blocks of 20Hz pulses for two seconds followed by 28 seconds of no stimulation.~Other Name: RTMS
Study NCT02289781 — intervention group
Intervention type: DEVICE
Intervention: posterior crowns
Description: teeth will be prepared to receive posterior crown made of either zirconia or metal-ceramic material
Study NCT03165006 — intervention group
Intervention type: PROCEDURE
Intervention: Mode of detection: Cancer detected at screening
Description: Cancers detected as a result of screening mammograms.
Study NCT03165006 — intervention group
Intervention type: PROCEDURE
Intervention: Mode of detection: Interval cancer
Description: Cancers diagnosed after a negative screening mammogram and before the next screening invitation (2 years in Spain)
Study NCT02941068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluconazole and caspofungin
Study NCT03039543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: Intravenous rocuronium was used to maintain moderate (TOF count of 1 or 2) neuromuscular blockade for patients with moderate neuromuscular blockade whereas intravenous rocuronium was used to maintain deep (TOF count of 0 with post-tetanic count of 2) neuromuscular blockade for patients with deep neuromuscular blockade.
Study NCT03039543 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: Intravenous rocuronium was used to maintain moderate (TOF count of 1 or 2) neuromuscular blockade for patients with moderate neuromuscular blockade whereas intravenous rocuronium was used to maintain deep (TOF count of 0 with post-tetanic count of 2) neuromuscular blockade for patients with deep neuromuscular blockade.
Study NCT03039543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Patients in moderate neuromuscular blockade are reversed with 2 mg/kg sugammadex at a TOF count of 1 or 2 and patients in the deep neuromuscular blockade are reversed with 4 mg/kg sugammadex at post-tetanic count of 2.
Study NCT03039543 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: Patients in moderate neuromuscular blockade are reversed with 2 mg/kg sugammadex at a TOF count of 1 or 2 and patients in the deep neuromuscular blockade are reversed with 4 mg/kg sugammadex at post-tetanic count of 2.
Study NCT02572817 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High-titer anti-influenza plasma
Description: Human plasma (FFP or FP24, 225-350 mL per unit or pediatric equivalent) with both an influenza A/H1N1 and A/H3N2 HAI titer of at least 1:80
Study NCT02572817 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Low-titer anti-influenza plasma
Description: Human plasma (FFP or FP24, 225-350 mL per unit or pediatric equivalent) with both an influenza A/H1N1 and A/H3N2 HAI titer of 1:10 or less
Study NCT00863889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depomedrol injection
Description: 1 cc of Depomedrol 80
Study NCT00863889 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine, Marcaine
Description: 4 cc of each local anesthetic
Study NCT03524456 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home blood pressure monitoring
Description: Participants would use a blood pressure device at home, that sends the readings automatically to the health center via SMS. The physicians would use this tool for medication management or rescheduling visits.
Study NCT00822003 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral GLP-1
Description: GLP-1 tablet (2mg)
Study NCT00822003 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control tablet
Study NCT01447849 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lubiprostone
Description: 24mcg twice a day (BID) 1 week
Study NCT01447849 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo pills twice a day for one week.
Study NCT02364232 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: bilateral training with and without mirror feedback
Study NCT02364232 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: bilateral training with and without mirror feedback
Study NCT01136889 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PFMT
Description: Women who have been successfully fitted with a vaginal pessary will be asked to attend five outpatient appointments over a 16 week period with a trained specialist women's health physiotherapist.
Study NCT02641886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jian Pi Yi Shen Hua Tan Granules
Description: Jianpi Yishen Huatan Granules contain Herba cistanche，Fructus Alpinia Oxyphyllae，Rhodiola rosea, Polygala tenuifolia willd and Coptis chinensis.Jianpi Yishen Huatan Granules dissolved in water of 100 ml ,po, bid of each 90-days cycle. Number of treatment cycles: one
Study NCT02641886 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: the placebo group
Description: Treat with the placebo which contain 5% of prescription of Jian Pi Yi Shen Hua Tan Granules and 95% dextrin.The placebo dissolved in water of 100 ml ,po, bid of each 90-days cycle. Number of cycles: one